Development of Organometallic S6K1 Inhibitors

[Image: see text] Aberrant activation of S6 kinase 1 (S6K1) is found in many diseases, including diabetes, aging, and cancer. We developed ATP competitive organometallic kinase inhibitors, EM5 and FL772, which are inspired by the structure of the pan-kinase inhibitor staurosporine, to specifically i...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Jie, Rajaratnam, Rajathees, Feng, Li, Salami, Jemilat, Barber-Rotenberg, Julie S., Domsic, John, Reyes-Uribe, Patricia, Liu, Haiying, Dang, Weiwei, Berger, Shelley L., Villanueva, Jessie, Meggers, Eric, Marmorstein, Ronen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289024/
https://www.ncbi.nlm.nih.gov/pubmed/25356520
http://dx.doi.org/10.1021/jm5011868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289024/
https://www.ncbi.nlm.nih.gov/pubmed/25356520
http://dx.doi.org/10.1021/jm5011868

Ejemplares similares